Skip to main content

FR
EN

Drupal

Main navigation EN

About Crossject
Our technology
Therapeutic areas

Main navigation 2 EN

Finances
News
- Our news
- Press releases
Careers
- Working at Crossject
Contact

Search

Enter the terms you wish to search for.

Home
Finances
Crossject achieves key ZEPIZURE® manufacturing milestone

Crossject achieves key ZEPIZURE® manufacturing milestone

Image

Date de parution

2024/07/18

PDF du document

PR_PilotB_Final.pdf222.93 KB

FINANCES CONTACT

Natasha DRAPEAU

+41 76 823 7527

Last financial releases

Crossject achieves key ZEPIZURE® manufacturing milestone

2024/07/18

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference

2024/07/15

Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

2024/07/10

Menu Pied de page

News
Legal information
Sitemap
Privacy Terms
Cookies

FOLLOW US